https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-us-litigation/
Karyopharm Announces Presentation Of Updated Phase 1 Selinexor Data In Patients With Treatment-Naïve Myelofibrosis At AACR 2023
– At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in
